Portland, MAINE2 Active Studies

Myeloproliferative Neoplasms Clinical Trials in Portland, MAINE

Find 2 actively recruiting myeloproliferative neoplasms clinical trials in Portland, MAINE. Connect with local research sites and explore new treatment options.

2
Active Trials
2
Sponsors
450
Enrolling

Recruiting Myeloproliferative Neoplasms Studies in Portland

About Myeloproliferative Neoplasms Clinical Trials in Portland

Myeloproliferative neoplasms (MPNs) are blood cancers in which the bone marrow overproduces red blood cells, platelets, or white blood cells. Types include polycythemia vera, essential thrombocythemia, and myelofibrosis. Treatment depends on the specific type and risk factors.

There are currently 2 myeloproliferative neoplasms clinical trials recruiting participants in Portland, MAINE. These studies are seeking a combined 450 participants. Research is being sponsored by Merck Sharp & Dohme LLC, Disc Medicine, Inc. Clinical trial participation is free and participants receive study-related medical care at no cost.

Myeloproliferative Neoplasms Clinical Trials in Portland — FAQ

Are there myeloproliferative neoplasms clinical trials in Portland?

Yes, there are 2 myeloproliferative neoplasms clinical trials currently recruiting in Portland, MAINE. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Portland?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Portland research site will contact you about next steps.

Are clinical trials in Portland free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Portland studies also compensate for your time and travel.

What myeloproliferative neoplasms treatments are being tested?

The 2 active trials in Portland are testing new therapies including novel drugs, biologics, and treatment approaches for myeloproliferative neoplasms.

Data updated March 2, 2026 from ClinicalTrials.gov